These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37163463)

  • 1. Discovery of C-5 Pyrazole-Substituted Pyrrolopyridine Derivatives as Potent and Selective Inhibitors for Janus Kinase 1.
    Lang JJ; Lv Y; Kobe B; Chen H; Tan Y; Chen L; Wang X; Mi P; Zheng X; Lin YW
    J Med Chem; 2023 May; 66(10):6725-6742. PubMed ID: 37163463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and evaluation of C-5 substituted pyrrolopyridine derivatives as potent Janus Kinase 1 inhibitors with excellent selectivity.
    Chen L; Tang Y; Lang JJ; Lin Y; Yu Z; Li X; Zheng X; Mi P; Lv Y; Lin YW
    Eur J Med Chem; 2024 Mar; 267():116210. PubMed ID: 38359535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
    Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
    Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.
    Labadie S; Dragovich PS; Barrett K; Blair WS; Bergeron P; Chang C; Deshmukh G; Eigenbrot C; Ghilardi N; Gibbons P; Hurley CA; Johnson A; Kenny JR; Kohli PB; Kulagowski JJ; Liimatta M; Lupardus PJ; Mendonca R; Murray JM; Pulk R; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward S; Zak M
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7627-33. PubMed ID: 23107482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-Amino-pyrrolopyridine-5-carboxamide: a novel scaffold for JAK1-selective inhibitors.
    Shin H; Kim MK; Chong Y
    Chem Pharm Bull (Tokyo); 2014; 62(3):217-20. PubMed ID: 24583775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors.
    Grimster NP; Anderson E; Alimzhanov M; Bebernitz G; Bell K; Chuaqui C; Deegan T; Ferguson AD; Gero T; Harsch A; Huszar D; Kawatkar A; Kettle JG; Lyne P; Read JA; Rivard Costa C; Ruston L; Schroeder P; Shi J; Su Q; Throner S; Toader D; Vasbinder M; Woessner R; Wang H; Wu A; Ye M; Zheng W; Zinda M
    J Med Chem; 2018 Jun; 61(12):5235-5244. PubMed ID: 29856615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and structure-activity relationship studies of 1,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 1 (JAK1) inhibitors.
    Kim W; Lee SM; Jeong PH; Jung JH; Kim YC
    Bioorg Med Chem Lett; 2022 Jan; 55():128451. PubMed ID: 34774741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative QSAR model generation using pyrazole derivatives for screening Janus kinase-1 inhibitors.
    Sarithamol S; Pushpa VL; Divya V; Manoj KB
    Chem Biol Drug Des; 2020 May; 95(5):503-519. PubMed ID: 32022397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.
    Schenkel LB; Huang X; Cheng A; Deak HL; Doherty E; Emkey R; Gu Y; Gunaydin H; Kim JL; Lee J; Loberg R; Olivieri P; Pistillo J; Tang J; Wan Q; Wang HL; Wang SW; Wells MC; Wu B; Yu V; Liu L; Geuns-Meyer S
    J Med Chem; 2011 Dec; 54(24):8440-50. PubMed ID: 22087750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors.
    Zimmermann K; Sang X; Mastalerz HA; Johnson WL; Zhang G; Liu Q; Batt D; Lombardo LJ; Vyas D; Trainor GL; Tokarski JS; Lorenzi MV; You D; Gottardis MM; Lippy J; Khan J; Sack JS; Purandare AV
    Bioorg Med Chem Lett; 2015 Jul; 25(14):2809-12. PubMed ID: 25987372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
    Dymock BW; See CS
    Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold.
    Yin Y; Chen CJ; Yu RN; Shu L; Zhang TT; Zhang DY
    Bioorg Med Chem; 2019 Apr; 27(8):1562-1576. PubMed ID: 30846405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity.
    Hansen BB; Jepsen TH; Larsen M; Sindet R; Vifian T; Burhardt MN; Larsen J; Seitzberg JG; Carnerup MA; Jerre A; Mølck C; Lovato P; Rai S; Nasipireddy VR; Ritzén A
    J Med Chem; 2020 Jul; 63(13):7008-7032. PubMed ID: 32462873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of triazolo [1,5-a] pyridine derivatives as novel JAK1/2 inhibitors.
    Lu K; Wu W; Zhang C; Liu Z; Xiao B; Yuan Z; Li A; Chen D; Zhai X; Jiang Y
    Bioorg Med Chem Lett; 2020 Jul; 30(14):127225. PubMed ID: 32527540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties.
    Siu T; Brubaker J; Fuller P; Torres L; Zeng H; Close J; Mampreian DM; Shi F; Liu D; Fradera X; Johnson K; Bays N; Kadic E; He F; Goldenblatt P; Shaffer L; Patel SB; Lesburg CA; Alpert C; Dorosh L; Deshmukh SV; Yu H; Klappenbach J; Elwood F; Dinsmore CJ; Fernandez R; Moy L; Young JR
    J Med Chem; 2017 Dec; 60(23):9676-9690. PubMed ID: 29156136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors.
    Duan JJ; Lu Z; Jiang B; Yang BV; Doweyko LM; Nirschl DS; Haque LE; Lin S; Brown G; Hynes J; Tokarski JS; Sack JS; Khan J; Lippy JS; Zhang RF; Pitt S; Shen G; Pitts WJ; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; McKinnon M; Fura A; Schieven GL; Wrobleski ST
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5721-5726. PubMed ID: 25453808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings.
    Yu V; Pistillo J; Archibeque I; Han Lee J; Sun BC; Schenkel LB; Geuns-Meyer S; Liu L; Emkey R
    Exp Hematol; 2013 May; 41(5):491-500. PubMed ID: 23340136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of azabenzimidazoles as potent JAK1 selective inhibitors.
    Vasbinder MM; Alimzhanov M; Augustin M; Bebernitz G; Bell K; Chuaqui C; Deegan T; Ferguson AD; Goodwin K; Huszar D; Kawatkar A; Kawatkar S; Read J; Shi J; Steinbacher S; Steuber H; Su Q; Toader D; Wang H; Woessner R; Wu A; Ye M; Zinda M
    Bioorg Med Chem Lett; 2016 Jan; 26(1):60-7. PubMed ID: 26614408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment.
    Zhang Y; Liang R; Chen CW; Mallano T; Dees C; Distler A; Reich A; Bergmann C; Ramming A; Gelse K; Mielenz D; Distler O; Schett G; Distler JHW
    Ann Rheum Dis; 2017 Aug; 76(8):1467-1475. PubMed ID: 28478401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.
    Zak M; Mendonca R; Balazs M; Barrett K; Bergeron P; Blair WS; Chang C; Deshmukh G; Devoss J; Dragovich PS; Eigenbrot C; Ghilardi N; Gibbons P; Gradl S; Hamman C; Hanan EJ; Harstad E; Hewitt PR; Hurley CA; Jin T; Johnson A; Johnson T; Kenny JR; Koehler MF; Bir Kohli P; Kulagowski JJ; Labadie S; Liao J; Liimatta M; Lin Z; Lupardus PJ; Maxey RJ; Murray JM; Pulk R; Rodriguez M; Savage S; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward SI; Xiao L; Xiao Y
    J Med Chem; 2012 Jul; 55(13):6176-93. PubMed ID: 22698084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.